Nintedanib Zentiva (Nintedanib Esylate)

Nintedanib, the active ingredient in Nintedanib Zentiva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It treats idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease and is used in combination therapy for non‑small cell lung cancer in appropriate patients.

GNH USA supplies Nintedanib Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is indicated for fibrotic lung diseases and certain oncology regimens, targeting pathways that drive fibroblast activity and tumor angiogenesis. - Idiopathic pulmonary fibrosis: slows disease progression and reduces decline in lung function. - Systemic sclerosis‑associated interstitial lung disease: improves pulmonary function and delays worsening. - Non‑small cell lung cancer (in combination therapy): enhances treatment efficacy when used with standard chemotherapy.

Nintedanib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Decreased appetite: reduced desire to eat. - Liver enzyme elevation: mild increase in ALT/AST.

Serious or Rare Side Effects: - Hepatotoxicity: significant liver injury requiring monitoring. - Bleeding events: increased risk of gastrointestinal or other bleeding. - Cardiovascular events: rare cases of myocardial infarction or stroke.

When prescribing Nintedanib, clinicians should consider several safety measures. - Dose adjustment: required in patients with moderate hepatic impairment. - Monitoring: regular liver function tests are recommended. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy: safety not established; avoid use during pregnancy. - Bleeding risk: assess patient history of bleeding disorders. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Nintedanib interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly raise plasma levels. - P‑glycoprotein substrates (e.g., digoxin): potential altered concentrations. - Antacids containing magnesium/aluminum: may reduce absorption if taken simultaneously.